Ongoing research will further elucidate any minor direct pathways (e.g., portal‐nerve or immune cell‐mediated effects), but even in their current understanding, GLP‐1 RAs represent a cornerstone of MASH therapy by virtue of treating the metabolic syndrome at the heart of the disease [83]. The gene discussed is GLP1R; the disease is metabolic dysfunction-associated steatohepatitis.